Alluvi, formerly BI 4744, represents a significant advance in obesity therapy. This dual activator targeting both glucagon-like peptide-1 and GIP receptors demonstrates compelling results in clinical studies, arguably surpassing available GLP-1 target activators. Early findings show meaningful {w